Snoqualmie, Wash.-based Light Sciences Oncology, a developer of light-activated cancer drugs, raised $30 million in a second funding round, even though it still has an IPO registration on file with the SEC. The latest funding closes out the company’s second round, which includes a $15 million investment by Fidelity Investments I wrote about here.
The company didn’t name its latest investors in its press release, but according to VentureWire they include Lehman Brothers, the hedge fund Deephaven Capital Management, the Malaysian Life Sciences Capital Fund, and Burrill & Co.
Test line: Technorati Profile
VentureBeatVentureBeat's mission is to be a digital town square for technical decision-makers to gain knowledge about transformative technology and transact. Our site delivers essential information on data technologies and strategies to guide you as you lead your organizations. We invite you to become a member of our community, to access:
- up-to-date information on the subjects of interest to you
- our newsletters
- gated thought-leader content and discounted access to our prized events, such as Transform 2021: Learn More
- networking features, and more